Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | An overview of optimal sequencing therapy in AML

Prapti Patel • 14 Dec 2021
ASH 2021
Acute Myeloid Leukemia Leukemia Azacitidine Venetoclax
VIALE-A VIALE-C

Prapti Patel, MD, University of Texas Southwestern Medical Center, Dallas, TX, gives an overview on therapy sequencing in acute myeloid leukemia (AML), and mentions the importance of the clinical data that is currently available, such as from the VIALE-A and VIALE-C trials (NCT02993523, NCT03069352). Dr Patel then mentions the importance of focusing on the biology of disease to better understand how to develop novel therapies in the future. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

Disclosures

BMS-Celgene, Agios: Membership on an entity’s Board of Directors or advisory committees; Peerview: Honoraria.

More from Prapti Patel

Venetoclax based combination therapy in AML: a real-world retrospective analysis
4:11
Venetoclax based combination therapy in AML: a real-world retrospective analysis
Prapti Patel • 14 Dec 2021
Updates from the Beat AML Master Trial
4:51
Updates from the Beat AML Master Trial
Prapti Patel • 14 Dec 2021
Treatment options for patients with AML that are not candidates for intensive chemotherapy
1:48
Treatment options for patients with AML that are not candidates for intensive chemotherapy
Prapti Patel • 14 Dec 2021

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals